LATEST UPDATES » Vol 23, No 06, June 2019 – Clinical trials — What's in a name?       » Study reveals mechanism behind ginger's warming effect on body       » China proposes major changes to pharmaceutical regulations       » Six plants native to Southeast Asia are promising cancer warriors       » Cancer cells are addicted to methionine       » World's first molecular swing      
Improving scalability of gene-modified cell therapy manufacturing
Indee Labs microfluidic vortex shedding potential alternative to current gene-modified cell therapy manufacturing

Indee Labs announced the publication of a proof-of-concept study demonstrating the efficacy of its gene-modified cell therapy (GMCT) development and manufacturing technology in Nature’s Scientific Reports.

The novel microfluidic method of intracellular delivery could provide a solution to one of the most significant challenges faced by the industry: scalability.

Unlike traditional medicines, GMCTs are made from patient and donor cells, which have been modified with the introduction of new genetic material.

Issues surrounding the most critical step in their manufacture, the delivery of new genes into cells, have held back both the pace of development of new treatments and scaled manufacturing of approved therapies such as CAR-T.

Most commonly this step is performed using engineered viruses; however, the GMCT market has been searching for non-viral alternatives due to supply challenges, costs, and other technical issues.

Indee Labs scientists managed successfully to deliver an mRNA construct into human T cells with high yield (i.e. transfection efficiency, cell viability, and cell recovery) and negligible perturbation to the T cell state, at a speed and scale that rivaled or exceeded conventional methods.

“Current in vitro and ex vivo intracellular delivery methods fail to meet the practical needs of GMCT development and manufacturing,” said Ryan S. Pawell, CEO of Indee Labs (USA). “Microfluidic vortex shedding (μVS) is already in development for a range of cell engineering methods outside of mRNA delivery to T cells.”

Other advantages of the μVS method include reduced costs, ease-to-scale, and substantially shorter lead times compared to clinical and commercial GMCT manufacturing using viruses.

This scalable gene-delivery technology for GMCT development and manufacturing does not damage immune cells and is an excellent alternative for discovery-stage research, clinical development, and commercial manufacturing of engineered or gene-modified human T cells.

They are working towards clinical development with multiple cell therapy clinics in both Australia and the United States.

The study was completed in collaboration with the University of Southern California Norris Comprehensive Cancer Center, the University of Sydney Medical School, and the University of South Australia Future Industries Institute.

Click here for the complete issue.

news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
What's cracking — Antibodies in ostrich eggs
Clinical trials — What's in a name?
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy